Sigilon Therapeutics, Inc.

Ownership Transactions Reported by 16 Insiders

Industry
Pharmaceutical Preparations
Location
100 Binney Street, Ste 600, Cambridge, MA

There are no Buy or Sell transactions made by insiders since 11/19/2024

Sigilon Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Daniel Griffith Anderson Director $30.2M Jun 2, 2021
May Orfali Chief Medical Officer $66.4K Feb 18, 2022
Brooke Story Director $59.1K May 26, 2022
ELI LILLY & Co 10%+ Owner $1.49K Aug 11, 2023
Philip Ashton-Rickardt Chief Scientific Officer Aug 11, 2023
Robert R. Ruffolo Director Aug 11, 2023
Flagship Ventures Fund V General Partner LLC 10%+ Owner Aug 11, 2023
John Cox Director Aug 11, 2023
Josias Pontes Chief Financial Officer Aug 11, 2023
Qing Sarah Yuan Ctoo Aug 11, 2023
Douglas G. Cole Director Aug 11, 2023
Coelho Rogerio Vivaldi PRESIDENT AND CEO, Director Aug 11, 2023
Eric D. Shaff Director Aug 11, 2023
Kavita Patel Director Aug 11, 2023
Stephen N. Oesterle Director Aug 11, 2023
Matthew Paul Kowalsky Chief Of Staff And Clo Aug 11, 2023

Recent Insider Transactions by Companies or Individuals for Sigilon Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.